In addition, we found that the estimated IC50 of AICAR (Acadesine, AMPK activator), ATRA (all-trans-retinoicacid), GDC0941 (PI3K inhibitor), JNK.Inhibitor.VIII, rapamycin (mTOR inhibitor) and thapsigargin (ATPase inhibitor) were also lower in MM patients in the high risk group based on our risk signature. This evidence concerns the gene MAPK8 and Miyoshi myopathy.